InMed Pharmaceuticals Inc (TO:IN) recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration as a topical formulation, a clean safety profile and that each of the two cannabinoid components plays an important and independent role in combating EB, which is an especially important finding from a regulatory point of view for any combination product. Additionally, the company’s biosynthesis program is tracking on schedule.
Positive preclinical results for INM-750
The company has conducted a plethora of preclinical studies for INM-750 for EB. Importantly, InMed has selected a topical formulation that has been able to show good permeability, clean safety/toxicology results and evidence that the two cannabinoid components of INM-750 play important and independent roles including anti-inflammation and keratin up-regulation.
To read the entire report Please click on the pdf File Below: